This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

22 Aug 2017

Bavarian Nordic closes transaction with Janssen Pharmaceuticals

Collaboration grants Janssen the exclusive rights to Bavarian Nordic’s MVA-BN technology for two additional programs, targeting vaccines against hepatitis B virus and the human immunodeficiency virus.

Bavarian Nordic has announced the closing of the transaction with Janssen Pharmaceuticals Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson regarding the license and collaboration agreement entered into on 27 July 2017. The transaction has been cleared under the Hart-Scott-Rodino Antitrust Improvements Act.

Consequently, Bavarian Nordic completes the direct placement to Johnson & Johnson Innovation - JJDC, Inc., consisting of 512,102 new shares of nominal value DKK 10 each (corresponding to approximately 1.63% of the Company's existing share capital) issued at a subscription price of DKK 405.1578 per new share raising gross proceeds to Bavarian Nordic of DKK 207.5 million.

Pursuant to section 10 of Executive Order no. 1526 of 9 December 2016 on Issuers' Disclosure Obligations, the total nominal value of Bavarian Nordic A/S' share capital after registration of the capital increase with the Danish Business Authority will amount to DKK 319,813,150, which is made up of 31,981,315 shares of a nominal value of DKK 10 each, corresponding to 31,981,315 votes.

The new shares will be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible.

Related News